Rubraca and Pulmonary oedema - a phase IV clinical study of FDA data

Summary:

Pulmonary oedema is reported as a side effect among people who take Rubraca (rucaparib camsylate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Amlodipine, and have Ovarian cancer.

The phase IV clinical study analyzes which people have Pulmonary oedema when taking Rubraca. It is created by eHealthMe based on reports of 10,770 people who have side effects when taking Rubraca from the FDA, and is updated regularly.

What is Rubraca?

Rubraca has active ingredients of rucaparib camsylate. eHealthMe is studying from 10,770 Rubraca users. Check the latest studies of Rubraca.

What is Pulmonary oedema?

Pulmonary oedema (fluid accumulation in the lungs) is found to be associated with 1,848 drugs and 1,967 conditions by eHealthMe. Check the latest studies of Pulmonary oedema.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

10,770 people reported to have side effects when taking Rubraca.
Among them, 23 people (0.21%) have Pulmonary oedema.

Among these 23 people:

How long have people been on Rubraca when they have Pulmonary oedema? *

What is the gender of people who have Pulmonary oedema when taking Rubraca? *

female: 100 %
male: 0.0 %

What is the age of people who have Pulmonary oedema when taking Rubraca? *

What are other drugs people take besides Rubraca? *

What are other side effects people have besides Pulmonary oedema? *

Fatigue (feeling of tiredness): 9 people, 39.13%
Dyspnea (difficult or laboured breathing): 8 people, 34.78%
Nausea (feeling of having an urge to vomit): 7 people, 30.43%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 7 people, 30.43%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 6 people, 26.09%
Blood Creatinine Increased: 5 people, 21.74%
Diabetes Mellitus Inadequate Control: 4 people, 17.39%
Cystitis Noninfective (non-infectious inflammation of the wall of the bladder): 4 people, 17.39%
Flank Pain (a distressing sensation experienced around the lower back and the upper abdomen): 4 people, 17.39%
High Blood Pressure: 3 people, 13.04%

What are the existing conditions these people have? *

Ovarian Cancer (cancer of ovary): 16 people, 69.57%
Malignant Peritoneal Neoplasm (cancer tumour of peritoneum): 6 people, 26.09%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 5 people, 21.74%
Cardiac Failure Congestive: 5 people, 21.74%
Diabetes: 5 people, 21.74%
Ejection Fraction (the percentage of blood that is pumped out of a filled ventricle as a result of a heartbeat): 5 people, 21.74%
High Blood Cholesterol: 5 people, 21.74%
High Blood Pressure: 5 people, 21.74%
Indigestion: 4 people, 17.39%
Hypocalcaemia (levels of calcium in blood serum are abnormally low): 4 people, 17.39%

* Approximation only. Some reports may have incomplete information.

Do you take Rubraca and have Pulmonary oedema?

- Check whether Pulmonary oedema is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rubraca:

Rubraca (10,770 reports)

Pulmonary oedema treatments and more:

Pulmonary oedema (53,624 reports)

Browse all side effects of Rubraca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pulmonary oedema:

Pulmonary oedema (1,848 drugs)

Browse all the conditions that are associated with Pulmonary oedema:

Pulmonary oedema (1,967 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rucaparib camsylate (the active ingredients of Rubraca) and Rubraca (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.